Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Increased to Hold at Zacks Research

Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Separately, Wall Street Zen cut Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Verrica Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $17.00.

Verrica Pharmaceuticals Trading Down 3.4%

Verrica Pharmaceuticals stock opened at $7.15 on Monday. The stock has a 50-day moving average of $5.98 and a two-hundred day moving average of $6.29. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.45 and a current ratio of 2.59. Verrica Pharmaceuticals has a one year low of $3.28 and a one year high of $9.82. The stock has a market cap of $122.84 million, a PE ratio of -4.53 and a beta of 1.54.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.14. The business had revenue of $5.02 million during the quarter, compared to analysts’ expectations of $4.51 million. On average, research analysts anticipate that Verrica Pharmaceuticals will post -2.24 EPS for the current fiscal year.

Institutional Trading of Verrica Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC boosted its holdings in shares of Verrica Pharmaceuticals by 75.1% in the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after acquiring an additional 479,732 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of Verrica Pharmaceuticals during the fourth quarter worth $5,878,000. Velan Capital Investment Management LP purchased a new position in shares of Verrica Pharmaceuticals during the fourth quarter worth $3,919,000. Boothbay Fund Management LLC acquired a new position in Verrica Pharmaceuticals during the third quarter valued at $1,210,000. Finally, Kalehua Capital Management LLC acquired a new position in Verrica Pharmaceuticals during the fourth quarter valued at $1,959,000. 42.45% of the stock is currently owned by institutional investors and hedge funds.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.